International Assets Investment Management LLC Purchases New Shares in Sanofi (NASDAQ:SNY)

International Assets Investment Management LLC purchased a new stake in Sanofi (NASDAQ:SNY) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 94,586 shares of the company’s stock, valued at approximately $4,704,000.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. grew its stake in Sanofi by 2.5% during the first quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock worth $546,804,000 after buying an additional 249,619 shares in the last quarter. Morgan Stanley grew its stake in Sanofi by 19.3% during the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock worth $374,513,000 after buying an additional 1,251,199 shares in the last quarter. Invesco Ltd. grew its stake in Sanofi by 2.3% during the first quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock worth $260,697,000 after buying an additional 112,404 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Sanofi by 276.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after buying an additional 2,468,271 shares in the last quarter. Finally, Lazard Asset Management LLC grew its stake in Sanofi by 0.8% during the first quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company’s stock worth $170,536,000 after buying an additional 25,457 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Morgan Stanley initiated coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock. Finally, StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $55.00.

Sanofi Stock Down 1.0 %

SNY stock opened at $45.80 on Wednesday. The stock has a market capitalization of $115.86 billion, a P/E ratio of 19.41, a price-to-earnings-growth ratio of 1.72 and a beta of 0.61. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The firm has a 50-day moving average price of $47.56 and a 200-day moving average price of $48.71.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. As a group, equities research analysts anticipate that Sanofi will post 4.16 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is currently 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.